What is RespireRx Pharmaceuticals Inc?
engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 849.13K.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.